# EDGAR Filing Document

**Accession Number:** 0001540013
**File Stem:** 0001104659-26-022929
**Filing Date:** 2026-3
**Character Count:** 17498
**Document Hash:** 4b9cb8a8825bac354a0afbff6e47e4b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-022929.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001104659-26-022929

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260303

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quipt Home Medical Corp.
- **CENTRAL INDEX KEY:** 0001540013
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40413
- **FILM NUMBER:** 26716154

**BUSINESS ADDRESS:**
- **STREET 1:** 1019 TOWN DRIVE
- **CITY:** WILDER
- **STATE:** KY
- **ZIP:** 41076
- **BUSINESS PHONE:** 859-878-2220

**MAIL ADDRESS:**
- **STREET 1:** 1019 TOWN DRIVE
- **CITY:** WILDER
- **STATE:** KY
- **ZIP:** 41076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Protech Home Medical Corp.
- **DATE OF NAME CHANGE:** 20200714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Patient Home Monitoring Corp.
- **DATE OF NAME CHANGE:** 20120119

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**March 3, 2026**

**Date of Report (Date of earliest event reported)**

**Quipt Home Medical Corp.**

**(Exact name of registrant as specified in its charter)**

**British Columbia, Canada**

**(State or other jurisdiction of incorporation)**

---

| | |
|:---|:---|
| **001-40413** | **N/A** |
| **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

---

| | |
|:---|:---|
| **1019 Town Drive** |  |
| **Wilder, Kentucky** | **41076** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(859) 878-2220**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Shares, without Par Value | QIPT | The Nasdaq Capital Market |
|  |  | Toronto Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On March 3, 2026, Quipt Home Medical Corp. ("Quipt") convened a special meeting (the "Meeting") of the holders of common shares (the "Shares") of Quipt (collectively, the "Shareholders") to vote on a proposal to consider, pursuant to an interim order of the Supreme Court of British Columbia, dated as of January 23, 2026, and, if deemed advisable, to pass, with or without variation, a special resolution (the "Arrangement Resolution"), approving an arrangement under Division 5 of Part 9 of the *Business Corporations Act* (British Columbia) pursuant to the arrangement agreement, dated as of December 14, 2025, by and among Quipt, 1567208 B.C. Ltd., and REM Aggregator, LLC. The Arrangement Resolution is described in more detail in the definitive management information circular and proxy statement filed with the Securities and Exchange Commission by Quipt on February 4, 2026.

As of the close of business on January 22, 2026, the record date of the Meeting, there were 44,329,972 Shares issued and outstanding and entitled to vote. A total 29,672,136 Shares were voted at the Meeting, representing approximately 66.93% of the issued and outstanding Shares as of the record date.

The number of votes cast for and against the Arrangement Resolution is set out below. There were no recorded abstentions or broker non-votes with respect to the Arrangement Resolution. Set forth below are the results of the Meeting:

***The Arrangement Resolution***

The Arrangement Resolution was approved, receiving the affirmative vote of approximately (i) 98.9% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting, and (ii) 98.7% of the votes cast by Shareholders, present in person or represented by proxy and entitled to vote at the Meeting, after excluding the votes cast by the Shareholders whose votes are required to be excluded under Multilateral Instrument 61-101 - *Protection of Minority Security Holders in Special Transactions*. In respect of the preceding two clauses, votes were received as follows:

*(i)* ---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**% Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**% Votes Against** |
| &nbsp;&nbsp;28737677 | &nbsp;&nbsp;98.9% | &nbsp;&nbsp;319623 | &nbsp;&nbsp;1.1% |

---

*(ii)* ---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**% Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**% Votes Against** |
| &nbsp;&nbsp;23929010 | &nbsp;&nbsp;98.68% | &nbsp;&nbsp;319623 | &nbsp;&nbsp;1.32% |

---

**Item 8.01. Other Events**

On March 3, 2026, Quipt issued a press release containing information about the voting results of the Meeting. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**<br>

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [99.1](tm267615d1_ex99-1.htm) | [Press release issued by Quipt Home Medical Corp. on March 3, 2026](tm267615d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **Quipt Home Medical Corp.** | **Quipt Home Medical Corp.** |
| Date: | March 3, 2026 | By: | /s/ Hardik Mehta |
|  |  |  | Hardik Mehta |
|  |  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**QUIPT HOME MEDICAL ANNOUNCES VOTING RESULTS FROM SPECIAL MEETING OF SHAREHOLDERS**

Cincinnati, Ohio – March 3, 2026 –‎ Quipt Home Medical Corp. (the "**Company**") (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its special meeting of holders (the "**Shareholders**") of common shares (the "**Shares**") of the Company held on March 3, 2026 (the "**Meeting**") in Sarasota, Florida. The Shareholders voted to approve the special resolution (the "**Arrangement Resolution**") approving the plan of arrangement under the *Business Corporations Act* (British Columbia), involving, among other things, the acquisition by affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC of all of the issued and outstanding Shares (the "**Arrangement**") for cash consideration of US$3.65 per Share.

The Arrangement Resolution required approval of: (i) at least 66⅔% of the votes cast by Shareholders, present in person or represented by proxy at the Meeting; and (ii) in accordance with Multilateral Instrument 61-101 - *Protection of Minority Security Holders in Special Transactions* ("**MI 61-101**"), a simple majority of votes cast by the Shareholders, present in person or represented by proxy and entitled to vote at the Meeting, excluding the votes in respect of Shares cast by any "interested party", any "related party" of an "interested party" or any "joint actor" (as such terms are defined in MI 61-101). Shareholders holding 29,672,136 Shares, representing approximately 66.93% of the outstanding Shares, were represented in person or by proxy at the Meeting. The Arrangement Resolution was approved by: (i) Shareholders holding 98.9% of the Shares voted; and (ii) Shareholders holding 98.7% of the Shares voted, after excluding the votes cast by the Shareholders whose votes were required to be excluded in determining minority approval under MI 61-101.

The Company is scheduled to seek a final order of the Supreme Court of British Columbia approving the Arrangement on March 5, 2026. Assuming all other terms and conditions, including applicable stock exchange and regulatory approvals, to the Arrangement are satisfied, it is expected that the Arrangement will be completed in the near term. Further information about the Arrangement can be found in the Company's definitive proxy statement and management information circular dated January 23, 2026 for the Meeting, which is available under the Company's profile on SEDAR+ and on the Company's website <u>https://quipthomemedical.com</u>., and has been filed with the SEC on the EDGAR website at <u>www.sec.gov</u>.

A Form 8-K in respect of the voting results has been filed with the SEC on the EDGAR website at <u>www.sec.gov</u>, on SEDAR+ under the Company's issuer profile at <u>www.sedarplus.com</u>.

**ABOUT QUIPT HOME MEDICAL CORP.‎**

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company's organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services, and making life easier for the patient.‎

**FORWARD-LOOKING STATEMENTS**

Certain statements contained in this press release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "**forward-looking statements**"). The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "postulate", "expect", "outlook", or the negatives thereof or variations of such words, and similar expressions as they relate to the Company are intended to identify forward-looking statements, including: the proposed Arrangement and terms thereof; and the anticipated completion of the Arrangement, including receipt of court and regulatory approval and satisfaction of closing conditions; and other statements that are not historical fact. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the ability to obtain the necessary regulatory, court, and other third party approvals for the Arrangement, the timing of obtaining such approvals and the risk that such approvals may not be obtained in a timely manner or at all, and the risk that such approvals may be obtained on conditions that are not anticipated; the timing of closing of the Arrangement; the risk that the conditions to the Arrangement are not satisfied on a timely basis or at all and the failure of the Arrangement to close for any other reason; the delisting of the Shares from the TSX and NASDAQ; the Company ceasing to be a reporting issuer under Canadian and U.S. federal securities laws and the timing thereof; the abilities of the parties to satisfy, in a timely manner, the other conditions to the closing of the Arrangement; the failure of the Arrangement to close for any other reason; and the ability to achieve the expected benefits of the Arrangement. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand received from the Department of Justice; increased competition; changes in foreign currency rates; the imposition of trade restrictions such as tariffs and retaliatory counter measures; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the SEC and available on EDGAR at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

For further information please visit our website at <u>www.quipthomemedical.com</u>, or contact:‎

Cole Stevens

VP of Corporate Development

Quipt Home Medical Corp.

‎859-300-6455

<u>cole.stevens@myquipt.com</u>

Gregory Crawford

Chief Executive Officer

Quipt Home Medical Corp.

‎859-300-6455

<u>investorinfo@myquipt.com</u>